1. Home
  2.  » 
  3. Expert Content
  4.  » 
  5. Cell Therapy
  6.  » Moving to Commercial Readiness with a Dedicated Analytical Platform for T-cell Therapies

Moving to Commercial Readiness with a Dedicated Analytical Platform for T-cell Therapies

Summary: Dr. Jef Pinxteren, Director of Process and Analytical Development at Catalent Cell and Gene Therapy, discusses a breadth of analytical methodologies, fill & finish approaches and manufacturing designs to accelerate CAR-T therapies to commercial readiness phase in this on-demand webinar.

 

Click here to download the Webinar